Hepatitis C News

Results of a recent systematic review and meta-analysis showed that sustained virologic response after hepatitis C therapy can reduce extrahepatic manifestations including insulin resistance and cardiovascular risks.

Patients with hepatitis C genotype 4 had high sustained virologic response rates with Harvoni over 8 weeks in treatment-naive cases without cirrhosis and over 12 weeks with ribavirin regardless of cirrhosis or treatment experience, according to recently published data from a phase 3 study in Egypt.

Zepatier was effective and well-tolerated in black patients with hepatitis C genotype 1 and 4 compared with overall reported safety profile, according to recently published data.

Findings presented at the International Liver Congress suggest that point-of-care testing for hepatitis C virus infection in community clinics in Australia was acceptable to patients and feasible, specifically for people who inject drugs, or PWID.

PARIS —Chairman of the department of medicine at Inova Fairfax Hospital, Virginia, Zobair M. Younossi, MD, discusses results of two studies on patient-reported outcomes among patients with hepatitis C in this exclusive interview from the International Liver Congress 2018.

PARIS — Results from a real-world cohort of patients with hepatitis C treated with Mavyret showed a sustained virologic response of 97%, according to an exclusive interview with Thomas Berg, MD, at the International Liver Congress.

PARIS — Rapid improvement in albumin levels after 4 weeks of treatment with direct-acting antivirals for hepatitis C significantly predicted long-term clinical and biochemical improvements among patients with advanced liver disease, according to a presentation at the International Liver Congress 2018.

PARIS — In this exclusive interview from the International Liver Congress 2018, Christophe Hezode, MD, discusses positive study results from two presentations on 8-week courses of Zepatier for hepatitis C in different patient populations.

Routine transgender health education is not common in U.S. medical schools. At Harvard Medical School and the University of California, San Francisco — two universities that have placed a premium on transgender health — the subject is currently covered only in elective courses. Infectious Disease News asked Katherine L. Margo, MD, associate professor of family medicine and community health in the Perelman School of Medicine at the University of Pennsylvania, if transgender health education should be required in medical school curricula.

In the last 15 years, Jae M. Sevelius, PhD, has seen positive changes in transgender health care, mainly from an awareness perspective.